Agios Launches Phase 2/3 Trial, RISE UP, for Mitapivat

Agios Launches Phase 2/3 Trial, RISE UP, for Mitapivat

315451

Agios Launches Phase 2/3 Trial, RISE UP, for Mitapivat

Agios Pharmaceuticals has launched a Phase 2/3 trial called RISE UP to test its investigational therapy mitapivat (AG-348) in people with sickle cell disease (SCD). The trial (NCT05031780), which is not yet recruiting, aims to enroll about 237 people with SCD, ages 16 and older. To be eligible, prospective participants must have hemoglobin levels between 5.5 and 10.5 grams per deciliter (g/dL) and have had two to 10 sickle cell pain crises in the previous…

You must be logged in to read/download the full post.